Preliminary STRATAS data support aggressive rotablation
This article was originally published in Clinica
Executive Summary
Aggressive Rotablator atherectomy safely improves acute gain, according to early data from the first STRATAS patients presented at the American Heart Association meeting in Anaheim (November 13th-16th). So far 32 pilot angiograms have been evaluated (see table), but eventually 500 patients will be included in the 15 site prospective randomised trial of routine versus aggressive burr use, said Dr Patrick Whitlow of the Cleveland Clinic Foundation, Ohio.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.